

ATTORNEY DOCKET NO. PBLI-P05-005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: S. Pestka

Examiner:

This is a Divisional of U.S. Serial No.: 08/489,071

Art Unit:

Filing Date: June 22, 2001

For: MODIFIED INTERFERONS

Express Mail Label No. EL 920 876 581

Date of Deposit: **June 25, 2001**

I hereby certify that this Application for a Continuation Application is being deposited with the United States Postal Service as Express Mail on the date indicated above and is addressed to: Commissioner for Patents, Attention Box Continuation Application, Washington, DC 20231.

Name:

Michael Crowley
MICHAEL CROWLEY

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application prior to examination as follows:

IN THE SPECIFICATION:

Please insert the following section on Page 1, line 1 of the specification immediately following the Title of the invention---

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application serial no. 08/489,071, filed June 9, 1995, which is a continuation of application serial no. 08/257,784, filed June 10, 1994, which is a continuation-in-part of application serial no. 08/076,231, filed June 11, 1993, now abandoned.---

IN THE CLAIMS:

Please cancel claims 1-17 and 21-36 without prejudice.

18. (Amended) A purified or recombinantly produced polypeptide comprising an amino acid sequence of human interleukin-2 encoded by a gene from a diseased cell, which amino acid sequence is a modification of the natural human interleukin-2.

Please add the following new claims:

37. The polypeptide of claim 18, which exhibits one of antiviral activity, growth inhibition activity and immunosuppressive activity.

38. The polypeptide of claim 18, which polypeptide is purified o homogeneity.

REMARKS

The present application is a divisional application of application serial no. 08/489,071, filed June 9, 1995. The parent application was subject to a restriction requirement, and the claims

MARKED-UP CLAIMS

18. (Amended) A purified or recombinantly produced polypeptide comprising an amino acid sequence of human interleukin-2 encoded by a gene from a diseased cell, which amino acid sequence is [having interleukin-2 activity, being derived uniquely from diseased cells and being] a modification of the natural human interleukin-2 [species].

of the present application have been amended to claim a non-elected embodiment in the parent application. Accordingly, early and favorable action on this application is respectfully solicited.

Dated: 6/25/01

Respectfully submitted,

by William G. Gosz

William G. Gosz

Reg. No. 27,787

Ropes & Gray

One International Place

Boston, MA

Attorneys for Applicant(s)

Tel. No. (617) 951-7000

RECEIVED
JUN 28 2001
FBI - BOSTON